PATENT CLAIM ANALYSIS

Application Number: 16001679
Application Type: Utility
Filing Date: 2018-06
Publication Date: 2018-10
Patent Classification: ["514", "255040"]

Abstract:
The present invention provides stable topical formulations of cetirizine that provide a comfortable formulation when instilled in the eye and is effective in the treatment of allergic conjunctivitis and/or allergic conjunctivitis. The invention further provides methods of treating allergic conjunctivitis and/or allergic rhinoconjunctivitis in a subject in need of such treatment by topical application of the cetirizine formulations of the invention directly to the eye.

Claim (Index 3):
A method for the treatment of the signs and symptoms of allergic conjunctivitis comprising topically administering to an eye of a subject in need thereof a topical ophthalmic formulation consisting of 0.1% (w/v) cetirizine, 1% Polyethylene Glycol 400, NF, 0.2% Dibasic Sodium Phosphate, Anhydrous, USP, 0.25% Hypromellose, USP, 0.1% Polysorbate 80, NF, 1.8% Glycerin, USP, 0.025% Edetate disodium, USP; 0.025% Edetate disodium, 0.01% Benzalkonium Chloride, NF, and Purified Water, USP and wherein the formulation has a pH 7 and does not contain a cyclodextrin or other solubilizing compound.

Metadata:
- Claim Count in Document: 3.0
- Percentile: 94.0
- Lexical Diversity: 1.76316
- Patent Class: 514.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['15456249', '13899321', '12888117', '14982258', '12724128']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8748326935991433
- 35 USC 102 Novelty (BERT): 0.7089009683340551
- Combined Prediction Score: 0.8582395210726345
- Mean Citation Score: 730.5944360000003
- Max Citation Score: 761.8855599999997
- Similarity Product: 752.2461083672307

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 0

Dataset: test